MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
马里兰州罗克维尔，2024年6月11日（GLOBE NEWSWIRE）——专注于开发、制造和商业化用于治疗癌症的创新单克隆抗体疗法的生物制药公司MacroGenics, Inc.（纳斯达克股票代码：MGNX）今天宣布，该公司的管理层将参加本月的以下投资者会议：
-
Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate presentation on Thursday, June 13, 2024, at 10:00am ET. MacroGenics' management will also participate in one-on-one meetings.
- 高盛 45第四 年度全球医疗保健会议（迈阿密海滩）。MacroGenics总裁兼首席执行官斯科特·科尼格医学博士、博士将于美国东部时间2024年6月13日星期四上午10点发表公司演讲。Macrogenics的管理层还将参加一对一的会议。
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
可以在Macrogenics网站投资者关系部分的 “活动与演讲” 下观看上述演讲的网络直播 http://ir.macrogenics.com/events.cfm。公司将在会议结束后的30天内在其网站上保留该网络直播的存档重播。
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
关于 MacroGenics, Inc.
MacroGenics（以下简称 “公司”）是一家生物制药公司，专注于开发、制造和商业化用于治疗癌症的基于单克隆抗体的创新疗法。该公司主要从其专有的下一代抗体技术平台套件中生成候选产品线，这些平台适用于广泛的治疗领域。MacroGenics的技术平台和蛋白质工程专业知识相结合，使公司能够开发出有前途的候选产品，并与全球制药和生物技术公司进行多项战略合作。欲了解更多信息，请访问公司的网站 wwwmacrogenics.com。MacroGenics 和 MacroGenics 徽标是 MacroGenics, Inc. 的商标或注册商标。
###
###
CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
联系人：吉姆·卡雷尔斯，高级副总裁，首席财务官1-301-251-5172， info@macrogenics.com
Source: MacroGenics, Inc.
资料来源：MacroGenics, Inc.